Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003377 · ClinicalTrials.gov registry record · Phase 1
Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix
A Phase 1 study of Cervical Cancer, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 13
- Study locations
NCT00003377: Completed Phase 1 study of Cervical Cancer, sponsored by Gynecologic Oncology Group.
NCT00003377 is a Phase 1 study of Cervical Cancer that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 29 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (95% lower). The trial reports 13 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003377, a Phase 1 study of Cervical Cancer, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 13
- Study locations
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Paclitaxel and cisplatin may increase the effectiveness of radiation therapy by making the tumor cells more sensitive to the radiation. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of paclitaxel when given with radiation therapy and cisplatin and to see how well they work in treating patients with cancer of the cervix that has spread to the lymph nodes in the pelvis and abdomen.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG paclitaxel
- RADIATION radiation therapy
- RADIATION brachytherapy
Study Locations (13)
Ohio
- MetroHealth's Cancer Care Center at MetroHealth Medical Center - Cleveland
- Cleveland Clinic Cancer Center at Fairview Hospital - Cleveland
- Cleveland Clinic Taussig Cancer Center - Cleveland
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University - Columbus
- Riverside Methodist Hospital Cancer Care - Columbus
Oklahoma
- Oklahoma University Medical Center - Oklahoma City
- Cancer Care Associates - Midtown Tulsa - Tulsa
Florida
- University of Miami Sylvester Comprehensive Cancer Center - Miami
Illinois
- University of Chicago Cancer Research Center - Chicago
Iowa
- Holden Comprehensive Cancer Center at University of Iowa - Iowa City
New Jersey
- Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees - Camden
North Carolina
- Comprehensive Cancer Center at Wake Forest University - Winston-Salem
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 1999-11 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
What the finished NCT00003377 record still lists
NCT00003377 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 4 interventions - of which cisplatin is the first listed.
NCT00003377 lists 13 locations in 8 states (Ohio, Oklahoma, Florida).
Frequently Asked Questions
What is clinical trial NCT00003377 about?
NCT00003377 is a clinical study titled "Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Paclitaxel and cisplatin may increase the effectiveness of radiation therapy by making the tumor cells more sensitive to the radiation. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they ...
What is the current status of trial NCT00003377?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 1999-11. Estimated completion is 2009-07.
What conditions does trial NCT00003377 study?
This clinical trial studies the following conditions: Cervical Cancer.
What interventions are being tested in trial NCT00003377?
The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), radiation therapy (RADIATION), brachytherapy (RADIATION).
Who is sponsoring clinical trial NCT00003377?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003377 being conducted?
This trial has 13 study locations across Florida, Illinois, Iowa, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003377's enrollment target sits among peer trials
29 124th of 144 higher than 21 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
-
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia